

Iowa Department of Human Services



Request for Prior Authorization IVABRADINE (CORLANOR®)

FAX Completed Form To

1 (877) 733-3195

Provider Help Desk 1 (844) 236-1464

IA Medicaid Member ID #	Patient name	DOB
Patient address		
Provider NPI	Prescriber name	Phone
Prescriber address		Fax
Pharmacy name	Address	Phone
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.		
Pharmacy NPI	Pharmacy fax NDC	

Prior authorization is required for ivabradine. Only FDA approved dosing will be considered. Payment will be considered under the following conditions:

1) Patient has a diagnosis of stable, symptomatic heart failure (NYHA Class II, III, or IV); and

- a) Patient is 18 years of age or older; and
- b) Patient has documentation of a left ventricular ejection fraction \leq 35%; and
- c) Patient is in sinus rhythm with a resting heart rate of ≥70 beats per minute; and
- d) Patient has documentation of blood pressure ≥90/50 mmHg; or
- 2) Patient has a diagnosis of stable symptomatic heart failure (NYHA/Ross class II to IV) due to dilated cardiomyopathy; and
 - a) Pediatric patient age 6 months and less than 18 years old; and
 - b) Patient has documentation of a left ventricular ejection fraction \leq 45%; and
 - c) Patient is in sinus rhythm with a resting heart rate (HR) defined below:
 - i. 6 to 12 months $HR \ge 105$ bpm
 - ii. 1 to 3 years $HR \ge 95$ bpm
 - iii. 3 to 5 years $HR \ge 75$ bpm
 - iv. 5 to 18 years $HR \ge 70$ bpm; and

3) Heart failure symptoms persist with maximally tolerated doses of at least one beta-blocker with proven mortality benefit in a heart failure clinical trial (e.g., carvedilol 50mg daily, metoprolol succinate 200mg daily, or bisoprolol 10mg daily), or weight appropriate dosing for pediatric patients, or patient has a documented intolerance or FDA labeled contraindication to beta-blockers; and

4) Patient has documentation of a trial and continued use with a preferred angiotensin system blocker at a maximally tolerated dose.

The required trials may be overridden when documented evidence is provided that the use of these agents would be medically contraindicated.

Non-Preferred

Corlanor®

Strength

Dosage Instructions

Quantity

Days Supply

Request for Prior Authorization-Continued IVABRADINE (CORLANOR®)

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Diagnosis:	
Stable, symptomatic heart failure (NYHA Class II to IV)): NYHA	A Class (≥ 18 years of age):
Stable, symptomatic heart failure (NYHA/Ross Class II to IV) d 18 years of age):NYHA/Ross Class:	
Other:	
Provide left ventricular ejection fraction:	Date obtained:
Provide resting heart rate in which patient is in sinus rhythm:	
Resting heart rate:	Date obtained:
For diagnosis of stable, symptomatic heart failure (NYHA Clas age:	ss II, III, or IV) in members ≥ 18 years of
Does patient have blood pressure ≥90/50mmHg?	
No Yes: Blood pressure:	Date obtained:
Treatment failure with maximally tolerated dose of beta-block failure clinical trial:	er with proven mortality benefit in a heart
Drug name & dose:	Trial dates:
Reason for failure:	_
Contraindication:	
Trial and continued use with a preferred angiotensin system b	blocker at maximally tolerated dose:
ug name & dose: Trial dates:	
Will an angiotensin system blocker be used concomitantly with iva	bradine? 🗌 No 🗌 Yes
Attach lab results and other documentation as necessary.	
Prescriber signature (Must match prescriber listed above.)	Date of submission

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for continues to be eligible for Medicaid.